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Editorial on the Research Topic
Mechanisms and Implications of the Aging of Cardiovascular Regenerative Cells
In this Research Topic, six groups discussed recent advances in the field of cardiovascular aging.
In particular, the biology of vascular regenerative cells has been dissected. The topic is of particular
relevance for scientists searching for solutions of the diseases of cardiovascular system, given the
advancing age of the population of developed countries (1, 2). Articles cover many aspects of this
problem, ranging from vascular aging, to cell reprogramming, touching organism development,
senescence, and mechanisms responsible for the progressive loss of the reparative ability of tissue
progenitors.
In their review, Moriya and Minamino discuss the topic of the aging of vascular cells and the
consequent impairment in angiogenesis. This appears to be a double-edged sword condition: due
to increased age-associated vascular cell senescence, old patients face delayed wound healing and
less efficient response to ischemia, but they are also somehow protected from cancer that can
progress only supported by new vascular structures that provide nutrition. Moreover, learning the
mechanisms that regulate the cellular dysfunction with age is instrumental to improve the efficacy
of therapeutic angiogenesis, a promising approach to cure ischemic diseases affecting mostly old
people. Authors point at central factors that need to be finely tuned to boost angiogenesis without
increasing malignancy. A central one is nitric oxide (NO), the production of which decreases in
aged cells.
Since elderly are the group of patients who mostly would benefit from cell therapy, the question
whether chronological age negatively impacts on induced pluripotent stem cell (iPSC) functionality
is a hot topic. In the article by Strässler et al. several aspects of the potential problem represented
by age-related limitations on the reprogramming process itself are addressed. Therefore, the
expansion in culture, and the differentiation of old donor-derived iPSC are discussed. Somehow
surprisingly, the reprogramming capabilities of somatic cells, although decreased with age, appears
to be maintained as iPSC from centenarians indicate (3, 4). However, centenarians represent a
group of subjects that may possess a genetic background that facilitate the escape from classical
age-associated cell changes as we and others also demonstrated (5). Maintenance in culture and
differentiation ability are re-started by the iPSC induction, but the obtained cellular product may
still be damaged by karyotype aberrations and DNA mutations accumulated in the process. Thus,
these limitations are still to be addressed before clinical exploitation may be possible.
The concept of cell senescence in cell reprogramming is discussed in the review by Passaro
and Testa. Although the heart was considered to be a post-mitotic organ, it is now recognized
that cardiac cells, including cardiomyocytes still possess the capability to proliferate and regenerate
damages. Senescence can therefore be seen as a negative condition that slows down the replicative
potential of cells, but it can also be beneficial for reprogramming by generating a pro-inflammatory
Beltrami and Spinetti Cardiovascular Regenerative Cells Aging: Mechanisms/Implications
environment by the acquisition of the senescent-associated
secretory phenotype (SASP) (6). This novel concept is dissected
in this article.
In their review, Castellan and Meloni discussed the transition
between the regenerative postnatal phase and the maturity.
Indeed, although neonatal mice can fully regenerate cardiac
damage, this “regenerative window” is rapidly lost 1 week after
birth. Although authors identified cardiomyocyte replenishment,
regression of fibrosis, and neovascularization as the three
key factors required for proper regeneration, most of the
current effort is devoted to the identification of mechanisms
unlocking cardiomyocyte renewal. In this regard, microRNAs
(miR) have been intensively studied. Among these, authors
discussed the role of miR-34a, members of the miR-15, miR-
590, miR-199, and the miR-17-92 cluster in modulating adult
cardiomyocyte proliferation. Authors subsequently discuss the
role played by both the transcriptional co-activators YAP/TAZ
and the transcription factor Meis1 in modulating the entry of
cardiomyocytes into the cell cycle. Last, authors remark the role
played by both immune cells (mostly macrophages) and that of
multipotent, tissue resident stem cells in cardiac regeneration.
Intriguingly, the importance of the latter in neonatal heart
regeneration has not been assessed yet.
Angelini et al. on the other hand considered the role played
by circulating factors on the physiology and senescence of cells
that have been tested in cardiovascular regeneration trials. This
is a hot topic, since heterochronic parabiosis experiments have
clearly shown that blood-born factors can revert age-related
tissue changes(7). The complex role of both Growth Hormone-
GH-/IGF-1 signaling and GDF-11 in development and, most
of all, aging is discussed. Next, authors present evidence of
the involvement of PAI-1, a factor whose levels increase with
organism aging, in senescence. Last, the role played by circulating
miRNA in organism aging is described, focusing on miR-34,
miR-146a, and miR-21.
Finally, Cesselli et al. reviewed the importance of redox
signaling and oxidative stress in the pathophysiology of
cardiovascular disease. Indeed, reactive oxygen species (ROS),
whose production is strictly regulated from a time and spatial
point of view, are neither good or bad in their essence, since
they are important regulators of cell fate, including stem cell
quiescence, self-renewal, and differentiation. Detrimental effects,
such as oxidative stress occur when ROS production becomes less
stringently controlled.
In conclusion, upon reaching maturity, mammalians
lose the ability to robustly regenerate organ damage, with
mechanisms, that are only partially understood. Moreover,
complex, interconnected, age-dependent mechanisms, that
include alteration of circulating factors, derangements of redox
signaling and oxidative stress, and inflammation alter the
biology of adult progenitors, negatively impacting the ability
to repair tissue damages. However, cellular senescence ignites
a paracrine response (SASP), which includes IL6, that is aimed
at orchestrating tissue repair and may favor dedifferentiation
and cell reprogramming in non-senescent cells. This relatively
novel concept has important implications in the generation
of iPSC from elderly people, that leaves a word of hope
for those patients that will need the most from these novel
approaches.
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